Saroj Kumar Shrestha

Mr. Saroj Kumar Shrestha

Department of Dental Pharmacology, Jeonbuk National University, Jeonju, Jeonbuk, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LIANG LILIANG LI
LIANG LI
MYMing Yang
Ming Yang
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
HKHyoungsu Kim
Hyoungsu Kim
WGWilliam Gerwick
William Gerwick
YSYunjo Soh
Yunjo Soh
Osteoclasts, bone-specified multinucleated cells produced by monocyte/macrophage, are involved in numerous bone destructive diseases such as arthritis, osteoporosis, and inflammation-induced bone loss. The osteoclast differentiation mechanism suggests a possible strategy to treat bone diseases. In this regard, we recently examined the in vivo impact of kalkitoxin (KT), a marine product obtained from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), on the macrophage colony-stimulating factor (M-CSF) and on the receptor activator of nuclear factor κB ligand (RANKL)-stimulated in vitro osteoclastogenesis and inflammation-mediated bone loss. We have now examined the molecular mechanism of KT in greater detail. KT decreased RANKL-induced bone marrow-derived macrophages (BMMs) tartrate-resistant acid phosphatase (TRAP)-multinucleated cells at a late stage. Likewise, KT suppressed RANKL-induced pit area and actin ring formation in BMM cells. Additionally, KT inhibited several RANKL-induced genes such as cathepsin K, matrix metalloproteinase (MMP-9), TRAP, and dendritic cell-specific transmembrane protein (DC-STAMP). In line with these results, RANKL stimulated both genes and protein expression of c-Fos and nuclear factor of activated T cells (NFATc1), and this was also suppressed by KT. Moreover, KT markedly decreased RANKL-induced p-ERK1/2 and p-JNK pathways at different time points. As a result, KT prevented inflammatory bone loss in mice, such as bone mineral density (BMD) and osteoclast differentiation markers. These experiments demonstrated that KT markedly inhibited osteoclast formation and inflammatory bone loss through NFATc1 and mitogen-activated protein kinase (MAPK) signaling pathways. Therefore, KT may have potential as a treatment for destructive bone diseases.

9 May 2022 in Journal of Periodontal & Implant Science
Verified
Journal Article
Open access
PDF file
MYMing Yang
Ming Yang
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
YSYunjo Soh
Yunjo Soh
SHSeok-Mo Heo
Seok-Mo Heo
Yang M, et al. J Periodontal Implant Sci. 2022 May;52:e18. https://doi.org/10.5051/jpis.2104060203

11 April 2022 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
Xiangdong SuXiangdong Su
Xiangdong Su
SYSeo Young Yang
Seo Young Yang
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
YSYunjo Soh
Yunjo Soh
Su XD, et al. J Vet Sci. 2022 Apr;23(4):e47. https://doi.org/10.4142/jvs.21246

1 September 2020 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MSMahesh Sapkota
Mahesh Sapkota
MGMing Gao
Ming Gao
LIANG LILIANG LI
LIANG LI
MYMing Yang
Ming Yang
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
YSYunjo Soh
Yunjo Soh

Verified
Journal Article
Open access
PDF file
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
KMKyung Hyun Min
Kyung Hyun Min
SKSe Woong Kim
Se Woong Kim
HKHyoungsu Kim
Hyoungsu Kim
WGWilliam Gerwick
William Gerwick
YSYunjo Soh
Yunjo Soh
Bone metastasis resulting from advanced breast cancer causes osteolysis and increases mortality in patients. Kalkitoxin (KT), a lipopeptide toxin derived from the marine cyanobacterium Moorena producens (previously Lyngbya majuscula), has an anti-metastatic effect on cancer cells. We verified that KT suppressed cancer cell migration and invasion in vitro and in animal models in the present study. We confirmed that KT suppressed osteoclast-soup-derived MDA-MB-231 cell invasion in vitro and induced osteolysis in a mouse model, possibly enhancing/inhibiting metastasis markers. Furthermore, KT inhibits CXCL5 and CXCR2 expression, suppressing the secondary growth of breast cancer cells on the bone, brain, and lungs. The breast-cancer-induced osteolysis in the mouse model further reveals that KT plays a protective role, judging by micro-computed tomography and immunohistochemistry. We report for the first time the novel suppressive effects of KT on cancer cell migration and invasion in vitro and on MDA-MB-231-induced bone loss in vivo. These results suggest that KT may be a potential therapeutic drug for the treatment of breast cancer metastasis.

1 January 2023 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
SSSaroj Kumar Shrestha
Saroj Kumar Shrestha
SKSe-Woong Kim
Se-Woong Kim
YSYunjo Soh
Yunjo Soh
Shrestha SK, et al. J Vet Sci. 2023 Aug;24:e69. https://doi.org/10.4142/jvs.23148